Peripheral Arterial Disease Trial, Recruiting NCT06979284 Sponsor: Hamilton Health Sciences Corporation Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT06979284
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have peripheral artery disease (PAD) in their legs that has progressed to a serious stage called chronic limb-threatening ischemia (CLTI) — meaning they have foot pain at rest, wounds that are not healing, or gangrene that has been present for at least two weeks, and where blood flow problems have been confirmed by medical testing
  • People whose blood pressure measurements at the ankle or toe fall below certain low thresholds (specific numbers vary depending on whether the main problem is pain at rest or tissue damage), confirming that blood flow to the foot is severely reduced
  • People who are scheduled to have a procedure to restore blood flow through a blood vessel using a non-surgical, catheter-based approach
  • People who have provided their informed consent to take part in the trial
  • People who have imaging (such as an X-ray dye study, ultrasound, CT, or MRI) showing a blockage or severe narrowing (more than 70%) in the leg arteries below the groin
  • People whose blocked artery below the knee is located in the upper two-thirds of that vessel, and where the vessel measures more than 2.5mm wide as estimated by the treating doctor
  • People where the furthest point of the blocked area is located more than 10cm above the ankle joint, and where the vessel from that point down to the ankle is open and clear of significant blockages

Who may not be able to join:

  • People with physical, health, social, or psychological conditions that, in the investigator's opinion, would make it difficult for them to take part in or complete the trial's follow-up visits
  • People whose medical condition means that a catheter-based procedure to restore blood flow is not medically suitable
  • People who have previously had, or are scheduled to have, a surgical procedure to restore blood flow in the same blood vessel being treated in the same leg
  • People who are confined to bed or completely unable to walk (note: walking with assistance is acceptable)
  • People whose life expectancy is estimated to be less than 12 months
  • People under 18 years of age
  • People with active inflammation of the blood vessels (vasculitis), a condition called Buerger's disease, or a sudden severe loss of blood flow to a limb
  • People who are planned to have an amputation above the ankle of the affected leg within four weeks of the procedure
  • People who have a significant blockage (more than 70%) in the arteries higher up (above the groin) that is not planned to be treated at the time of the procedure or within 30 days of it
  • People who have previously had an amputation of the same leg at a level higher than the toes or front of the foot, or who had a major amputation of the other leg less than one year ago and are not able to walk independently
  • People whose tissue damage is so extensive that it would require complex foot reconstruction or certain types of major foot amputations — this includes specific situations such as:
    • Bone infection (osteomyelitis) extending beyond the base of the toes
    • Gangrene affecting the sole of the foot, the middle of the foot, or the heel
    • Deep wounds or large shallow wounds (larger than 3cm) on the sole of the foot, mid-foot, or heel
    • Full-thickness wounds on the heel
    • Any wound involving the heel bone
    • Wounds requiring surgical skin flap procedures or complex management due to large areas of tissue loss
    • Full-thickness wounds on the top of the foot where tendon or bone is exposed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 905-521-2100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hamilton Health Sciences Corporation
Registry
ClinicalTrials.gov
Start date
5 December 2025
Est. completion
1 July 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Time-to-first occurrence of MALE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov